Want to see SE:SCIB full AI Analyst Report?
SCIB Stock Chart & Stats
kr0.33
>-kr0.01(-1.65%)
At close: 4:00 PM EST
kr0.33
>-kr0.01(-1.65%)
Day’s Range― - ―
52-Week Rangekr13.60 - kr51.34
Previous CloseN/A
Volume1.41K
Average Volume (3M)4.42K
Market Cap
kr203.16M
Enterprise Valuekr318.37M
Total Cash (Recent Filing)kr37.15M
Total Debt (Recent Filing)kr23.21M
Price to Earnings (P/E)―
Beta-0.18
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-15.91
Shares Outstanding14,059,788
10 Day Avg. Volume6,086
30 Day Avg. Volume4,419
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)18.68
Price to Sales (P/S)3.07
P/FCF Ratio-1.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)7.92
Revenue Forecast (FY)kr65.90M
Bulls Say, Bears Say
Bulls Say
Improving Revenue GrowthRevenue momentum improved materially from roughly 0.4% growth in 2025 to about 14.2% in the TTM period, indicating stronger commercial traction. If sustained, expanding adoption can build a larger installed base and support recurring usage revenue.
Solid Gross MarginA gross margin of approximately 59% indicates that Nevisense-related revenue retains meaningful contribution after direct costs. This provides a foundation for funding commercial investment and eventual operating leverage if revenue expands faster than the cost base.
Currently Moderate LeverageCurrent leverage appears moderate, with debt-to-equity near 0.41 and total debt well below total assets. This is a more manageable balance-sheet position than a highly leveraged profile, although continued losses remain important to future financial flexibility.
Bears Say
Deep Persistent LossesThe approximately -208% TTM net margin shows that the company remains far from sustainable profitability, with operating costs substantially exceeding its current revenue scale. Persistent losses can delay self-funded growth and increase dependence on additional capital over the coming quarters.
Heavy Cash BurnStrongly negative operating and free cash flow indicate that the business is consuming substantial cash rather than financing operations internally. Even with reported revenue growth, this burn rate may require external funding until scale and cost control improve materially.
Balance-Sheet VolatilityThe sharp change in leverage demonstrates meaningful balance-sheet volatility, while continued large losses could pressure equity again. This creates an ongoing funding and dilution risk if the company cannot improve profitability and cash generation before reserves or financing capacity tighten.
SciBase Holding AB News
SCIB FAQ
What was SciBase Holding AB’s price range in the past 12 months?
SciBase Holding AB lowest stock price was kr13.60 and its highest was kr51.34 in the past 12 months.
What is SciBase Holding AB’s market cap?
SciBase Holding AB’s market cap is kr203.16M.
When is SciBase Holding AB’s upcoming earnings report date?
SciBase Holding AB’s upcoming earnings report date is Nov 12, 2026 which is in 33 days.
How were SciBase Holding AB’s earnings last quarter?
SciBase Holding AB released its earnings results on Aug 19, 2026. The company reported -kr2.691 earnings per share for the quarter.
Is SciBase Holding AB overvalued?
According to Wall Street analysts SciBase Holding AB’s price is currently Overvalued.
Does SciBase Holding AB pay dividends?
SciBase Holding AB does not currently pay dividends.
What is SciBase Holding AB’s EPS estimate?
SciBase Holding AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SciBase Holding AB have?
SciBase Holding AB has 14,059,788 shares outstanding.
What happened to SciBase Holding AB’s price movement after its last earnings report?
SciBase Holding AB reported an EPS of -kr2.691 in its last earnings report. Following the earnings report the stock price went down -11.362%.
Which hedge fund is a major shareholder of SciBase Holding AB?
Currently, no hedge funds are holding shares in SE:SCIB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SciBase Holding AB
SciBase Holding AB (publ), a medical technology firm founded in 1998 and headquartered in Sundbyberg, Sweden, specializes in the global development and distribution of instruments for diagnosing skin cancer and other dermatological issues. Their key offerings, Nevisense and Nevisense Go, comprise a point-of-care platform designed for the detection of melanoma and non-melanoma skin cancers, as well as for evaluating skin barrier function. The company also maintains a collaborative agreement with the Advanced Dermatology and Cosmetic Surgery (ADCS) group.